Viatris Q2 earnings rise 11%, free cash flow doubles, boosting shareholder returns and growth outlook.

Viatris reported a strong Q2 with adjusted net income and earnings per share up 11%, alongside a doubling of free cash flow compared to last year. The company is successfully reducing debt while using increased cash flow to fund share buybacks and dividends, signaling solid shareholder returns. Progress in its drug pipeline and new product approvals add potential for future growth, with key Phase 3 trials nearing important milestones. Despite uncertainties related to China, Viatris raised its guidance and maintains a strong buy rating due to improved earnings visibility and attractive valuation.